Modulation of immune responses using adjuvants to facilitate therapeutic vaccination

Publsher's version (útgefin grein)Therapeutic vaccination offers great promise as an intervention for a diversity of infectious and non-infectious conditions. Given that most chronic health conditions are thought to have an immune component, vaccination can at least in principle be proposed as a therapeutic strategy. Understanding the nature of protective immunity is of vital importance, and the progress made in recent years in defining the nature of pathological and protective immunity for a range of diseases has provided an impetus to devise strategies to promote such responses in a targeted manner. However, in many cases, limited progress has been made in clinical adoption of such approaches. This in part results from a lack of safe and effective vaccine adjuvants that can be used to promote protective immunity and/or reduce deleterious immune responses. Although somewhat simplistic, it is possible to divide therapeutic vaccine approaches into those targeting conditions where antibody responses can mediate protection and those where the principal focus is the promotion of effector and memory cellular immunity or the reduction of damaging cellular immune responses as in the case of autoimmune diseases. Clearly, in all cases of antigen-specific immunotherapy, the identification of protective antigens is a vital first step. There are many challenges to developing therapeutic vaccines beyond those associated with prophylactic diseases including the ongoing immune responses in patients, patient heterogeneity, and diversity in the type and stage of disease. If reproducible biomarkers can be defined, these could allow earlier diagnosis and intervention and likely increase therapeutic vaccine efficacy. Current immunomodulatory approaches related to adoptive cell transfers or passive antibody therapy are showing great promise, but these are outside the scope of this review which will focus on the potential for adjuvanted therapeutic active vaccination strategies.This article/publication is based upon work from COST Action CA16231 ENOVA (European Network of Vaccine Adjuvants), supported by COST (European Cooperation in Science and Technology—www.cost.eu).Peer Reviewe

Insect Antimicrobial Peptide Complexes Prevent Resistance Development in Bacteria.

In recent decades much attention has been paid to antimicrobial peptides (AMPs) as natural antibiotics, which are presumably protected from resistance development in bacteria. However, experimental evolution studies have revealed prompt resistance increase in bacteria to any individual AMP tested. Here we demonstrate that naturally occurring compounds containing insect AMP complexes have clear advantage over individual peptide and small molecule antibiotics in respect of drug resistance development. As a model we have used the compounds isolated from bacteria challenged maggots of Calliphoridae flies. The compound isolated from blow fly Calliphora vicina was found to contain three distinct families of cell membrane disrupting/permeabilizing peptides (defensins, cecropins and diptericins), one family of proline rich peptides and several unknown antimicrobial substances. Resistance changes under long term selective pressure of the compound and reference antibiotics cefotaxime, meropenem and polymyxin B were tested using Escherichia coli, Klebsiella pneumonia and Acinetobacter baumannii clinical strains. All the strains readily developed resistance to the reference antibiotics, while no signs of resistance growth to the compound were registered. Similar results were obtained with the compounds isolated from 3 other fly species. The experiments revealed that natural compounds containing insect AMP complexes, in contrast to individual AMP and small molecule antibiotics, are well protected from resistance development in bacteria. Further progress in the research of natural AMP complexes may provide novel solutions to the drug resistance problem

MIC changes in bacterial strains exposed to selection by the compounds containing <i>C</i>. <i>vicina</i> AMP complex or conventional antibiotics.

<p>(A) <i>E</i>. <i>coli</i> 774.1 (reference antibiotic cefotaxime). <i>E</i>. <i>coli</i> antibiotic sensitive strain 774.1 was exposed to selection by the AMP complex or cefotaxime in the course of 25 daily transfers as explained in Materials and Methods section. Resistance rate is expressed as fold change in MICs. 1 MIC unit is equal to the MIC value at transfer 1 (250 mg/L for the compound and 0.125 mg/L for cefotaxime, correspondingly). Selection by cefotaxime caused 16-fold increase of MIC while no signs of MIC change were found in the compound treated population. Difference in the compound versus cefotaxime effects on the resistance development was highly significant according to Wilcoxon test statistics (W = 276, n = 23, P<0.001). (B) <i>E</i>. <i>coli</i> 774.1 (reference antibiotic polymyxin B). The strain was exposed to selection by the compound or polymyxin B in the course of 15 daily transfers. 1 MIC unit is equal to the MIC value at transfer 1 (250 mg/L for the compound and 8.0 mg/L for polymyxin B, correspondingly). Difference in the compound versus polymyxin B effects on the resistance development was highly significant according to Wilcoxon test statistics (W = 91, n = 13, P<0.022). (C) <i>E</i>. <i>coli</i> 863.1 (reference antibiotic meropenem). <i>E</i>. <i>coli</i> antibiotic multiresistant meropenem sensitive strain 863.1 was exposed to selection by the compound or meropenem in the course of 15 daily transfers. 1 MIC unit is equal to the MIC value at transfer 1 (500 mg/L for the compound and 0.125 mg/L for meropenem, correspondingly). Difference in the compound versus meropenem effects on the resistance development was highly significant according to Wilcoxon test statistics (W = 78, n = 12, P<0.020). (D) A. baumannii 882.2 (reference antibiotic polymyxin B). <i>A</i>. <i>baumannii</i> antibiotic multiresistant strain 882.2 was exposed to selection by the AMP complex or polymyxin B in the course of 35 daily transfers. 1 MIC unit is equal to the MIC value at transfer 1 (500 mg/L for the compound and 2 mg/L for polymyxin B, correspondingly). Difference in the compound versus polymyxin B effects on the resistance development were highly significant according to Wilcoxon test statistics (W = 561, n = 33, P<0.001).</p

Estimation of performance parameters of turbine engine components using experimental data in parametric uncertainty conditions

Gas Path Analysis and matching turbine engine models to experimental data are inverse problems of mathematical modelling which are characterized by parametric uncertainty. It results from the fact that the number of measured parameters is significantly less than the number of components’ performance parameters needed to describe the real engine. Inthese conditions, even small measurement errors can result in a high variation of results, and obtained efficiency, lossfactors etc. can appear out of the physical range. The paper presents new method for setting a priori information about the engine and its performance in view of fuzzy sets, forming objective functions and scalar convolutions synthesis of these functions to estimate gas-path components’ parameters. The comparison of the proposed approach with traditional methods showed that its main advantage is high stability of estimation in the parametric uncertainty conditions. It reduces scattering, excludes incorrect solutions which do not correspond to a priori assumptions, and also helps to implement the Gas Path Analysis at the limited number of measured parameters

Resistance before and after selection by <i>Calliphora vomitoria</i>, <i>Lucilia sericata</i> and <i>Musca domestica</i> AMP complexes in <i>E. coli</i> 774.1 strain.

<p>*KR–ratio of MIC after selection to MIC before selection</p><p>Resistance before and after selection by <i>Calliphora vomitoria</i>, <i>Lucilia sericata</i> and <i>Musca domestica</i> AMP complexes in <i>E. coli</i> 774.1 strain.</p

Resistance development under selective pressure of cefotaxime, meropenem, polymyxin B and <i>C</i>. <i>vicina</i> AMP complex.

<p>*K_R−ratio of MIC after selection to MIC before selection.</p><p>Resistance development under selective pressure of cefotaxime, meropenem, polymyxin B and <i>C</i>. <i>vicina</i> AMP complex.</p

MIC changes in the course of selection by the combinations of antimicrobial agents.

<p>(A) Cefotaxime and polymyxin B combination. <i>E</i>. <i>coli</i> antibiotic sensitive strain 774.1 was exposed to selection by cefotaxime, polymyxin B or a mixture of polymyxin B and cefotaxime in the course of 15–20 daily transfers. Resistance level is expressed as fold change in MICs. 1 MIC unit is equal to 8 mg/L for polymyxin B, 0.125 mg/L for cefotaxime and 1.0 mg/L for a mixture containing cefotaxime and polymyxin B in ratio 1:32, correspondingly. Selection by cefotaxime, polymyxin B or a mixture of the antibiotics caused identical 8-fold increase of MIC. Differences in the mixture versus cefotaxime (W = 19, n = 6, P = 0.062) and polymyxin B (W = 19, n = 6, P = 0.062) effects on the rate of resistance development were statistically insignificant according to Wilcoxon test. (B) The compound containing <i>C</i>. <i>vicina</i> AMP complex and cefotaxime combination. <i>E</i>. <i>coli</i> strain 774.1 was exposed to selection by cefotaxime alone or cefotaxime in combination with the compound (50 mg/L) in the course of 15 daily transfers. Resistance level is expressed as cefotaxime fold change in MICs. 1 MIC unit corresponds to MIC value of cefotaxime at transfer 1 (0.125 mg/L). Delay of cefotaxime resistance development in presence of the compound sub-inhibitory concentration was statistically significant according to Wilcoxon test (W = 78, n = 12, P<0.02) and repeated measures ANOVA test (F = 16.465, η = 29, P = 0.001).</p

Antibacterial activity, chromatographic, mass spectrometric and structural characteristics of active AMPs present in <i>C</i>. <i>vicina</i> AMP complex.

<p>Antibacterial activity, chromatographic, mass spectrometric and structural characteristics of active AMPs present in <i>C</i>. <i>vicina</i> AMP complex.</p

Antibiotic resistance spectra of bacterial strains used in selection experiments.

<p>Antibiotic abbreviations: Amc—amoxicillin/clavulanic acid, Ami–amikacin, Net–netilmicin, Gen–gentamicin, Ipm–imipenem, Mem–meropenem, Chl–chloramphenicol, Cip–ciprofloxacin, Cfp—cefoperazone, Cfp/sul–cefoperazone, Sul—sulbactam, Caz–ceftazidime, Ctx–cefotaxime, Cpe–cefepime.</p><p>*- no data.</p><p>Antibiotic resistance spectra of bacterial strains used in selection experiments.</p

Chromatographic characteristics of naturally occurring compound containing <i>C</i>. <i>vicina</i> AMP complex.

<p>1 mg of purified complex isolated from bacteria challenged <i>C</i>. <i>vicina</i> larvae were subjected to reversed-phase HPLC fractionation with 1 min intervals as described in Materials and Methods section. Optical density of the fractions was measured in mAU units at 214 nm wave length. 53 fractions were individually collected, lyophilized and stored at -70°C until further antimicrobial activity and mass spectrometry analyses summarized in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0130788#pone.0130788.t002" target="_blank">Table 2</a>.</p